Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios bial s.a. - bezafibrato - comprimido de liberaciÓn prolongada - 400 mg - bezafibrato 400 mg - bezafibrato

Spania - spansk - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

marion merrell s.a. - rifampicina; isoniazida; pirazinamida - comprimido recubierto - 120 mg/50 mg/300 mg - rifampicina 120 mg; isoniazida 50 mg; pirazinamida 300 mg - rifampicina, pirazinamida e isoniazida

USA - engelsk - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - rifampin (unii: vjt6j7r4tr) (rifampin - unii:vjt6j7r4tr), isoniazid (unii: v83o1voz8l) (isoniazid - unii:v83o1voz8l), pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - rifampin 120 mg - rifater is indicated in the initial phase of the short-course treatment of pulmonary tuberculosis. during this phase, which should last 2 months, rifater should be administered on a daily, continuous basis (see dosage and administration). following the initial phase and treatment with rifater, treatment should be continued with rifampin and isoniazid (e.g., rifamate) for at least 4 months. treatment should be continued for a longer period of time if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is hiv positive. in the treatment of tuberculosis, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. bacteriologic smears or cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to r

Italia - italiensk - AIFA (Agenzia Italiana del Farmaco)

sanofi s.r.l. - rifampicina, pirazinamide e isoniazide - rifampicina, pirazinamide e isoniazide

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - pyrazinamide; rifampicin; isoniazid - oral tablet - 300mg ; 120mg ; 50mg

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - pyrazinamide; rifampicin; isoniazid - oral tablet - 300mg ; 120mg ; 50mg

Sveits - tysk - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - rifampicinum, isoniazidum, pyrazinamidum - überzogene tabletten - rifampicinum 120 mg, isoniazidum 50 mg, pyrazinamidum 300 mg, natrii laurilsulfas, calcii stearas, saccharum 105 mg, carmellosum natricum, povidonum k 30, magnesii subcarbonas levis, kaolinum ponderosum, acaciae gummi, talcum, silica colloidalis anhydrica, aluminii oxidum hydricum, e 171, e 172 (rubrum) pro compresso obducto corresp. natrium 2.83 mg. - tuberculose - synthetika

Slovenia - slovensk - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sanofi-aventis d.o.o. - izoniazid; pirazinamid; rifampicin - obložena tableta - izoniazid 50 mg / 1 tableta  pirazinamid300 mg / 1 tableta  rifampicin120 mg / 1 tableta; pirazinamid 300 mg / 1 tableta  rifampicin120 mg / 1 tableta; rifampicin 120 mg / 1 tableta - rifampicin, pirazinamid in izoniazid

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sanofi-aventis deutschland gmbh (8030868) - isoniazid; rifampicin; pyrazinamid - überzogene tablette - isoniazid (00155) 50 milligramm; rifampicin (02599) 120 milligramm; pyrazinamid (03555) 300 milligramm

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

sanofi winthrop industrie - rifampicine 120 mg; isoniazide 50 mg; pyrazinamide 300 mg - comprimé - 120 mg - pour un comprimé > rifampicine 120 mg > isoniazide 50 mg > pyrazinamide 300 mg - antimycobactérien, antituberculeux - classe pharmacothérapeutique : antimycobactérien, antituberculeux - code atc : j04am05.ce médicament est indiqué en association à d’autres antibiotiques dans le traitement de la tuberculose.